Literature DB >> 24261768

The role of TNF-α in a murine model of Kawasaki disease arteritis induced with a Candida albicans cell wall polysaccharide.

Toshiaki Oharaseki1, Yuki Yokouchi, Hitomi Yamada, Hiroshi Mamada, Satoshi Muto, Kiyomi Sadamoto, Noriko Miura, Naohito Ohno, Tsutomu Saji, Shiro Naoe, Kei Takahashi.   

Abstract

OBJECTIVES: Various inflammatory cytokines, including tumor necrosis factor-α (TNF-α), have been reported to play roles in Kawasaki disease (KD). Recently, anti-TNF-α therapy was reported to show efficacy in patients who do not respond to high-dose intravenous immunoglobulin therapy. However, there are many gaps in our understanding of the role that TNF-α plays in the development of KD arteritis as well as whether anti-TNF-α therapy causes any histological changes in the arteritis. Accordingly, the present histopathological study was carried out to elucidate the inhibitory effect of anti-TNF-α therapy on vasculitis as well as the role of TNF-α in the development of vasculitis in a murine model of KD vasculitis.
METHODS: We used two anti-TNF-α drugs (etanercept and infliximab) to treat a Candida albicans-induced murine model of KD vasculitis. We investigated the histopathological changes in terms of the incidence of vasculitis, the scope of lesions and the degree of inflammation.
RESULTS: Administration of etanercept to the mice reduced not only the incidence of vasculitis but also the scope of lesions and the degree of inflammation.
CONCLUSION: Based on the histological findings, TNF-α is deeply involved in the development of vasculitis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24261768     DOI: 10.3109/14397595.2013.854061

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  9 in total

1.  Should infliximab be used as an adjuvant to IVIG in the treatment of children with Kawasaki disease who are at high risk for resistance to conventional therapy?

Authors:  Shelby Davies; Gabrielle Gold-von Simson
Journal:  Pediatr Cardiol       Date:  2013-06-15       Impact factor: 1.655

2.  TNF-α blockers for the treatment of Kawasaki disease in children.

Authors:  Noyuri Yamaji; Katharina da Silva Lopes; Tetsuo Shoda; Kazue Ishitsuka; Tohru Kobayashi; Erika Ota; Rintaro Mori
Journal:  Cochrane Database Syst Rev       Date:  2019-08-16

3.  Genome-Wide Association Study Identifies Novel Susceptibility Genes Associated with Coronary Artery Aneurysm Formation in Kawasaki Disease.

Authors:  Ho-Chang Kuo; Sung-Chou Li; Mindy Ming-Huey Guo; Ying-Hsien Huang; Hong-Ren Yu; Fu-Chen Huang; Fuyong Jiao; Hsing-Chun Kuo; Jorge Andrade; Wen-Ching Chan
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

4.  Monoclonal antibody therapy for Kawasaki disease: a protocol for systematic reviews and meta-analysis.

Authors:  Osamu Nomura; Sayaka Fukuda; Erika Ota; Hiroshi Ono; Akira Ishiguro; Tohru Kobayashi
Journal:  Syst Rev       Date:  2016-04-12

Review 5.  Kawasaki disease: pathophysiology and insights from mouse models.

Authors:  Magali Noval Rivas; Moshe Arditi
Journal:  Nat Rev Rheumatol       Date:  2020-05-26       Impact factor: 20.543

6.  A novel mouse model of coronary stenosis mimicking Kawasaki disease induced by Lactobacillus casei cell wall extract.

Authors:  Eisuke Suganuma; Satoshi Sato; Satoko Honda; Atsuko Nakazawa
Journal:  Exp Anim       Date:  2020-01-13

Review 7.  Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison.

Authors:  Chetan Sharma; Madhusudan Ganigara; Caroline Galeotti; Joseph Burns; Fernando M Berganza; Denise A Hayes; Davinder Singh-Grewal; Suman Bharath; Sujata Sajjan; Jagadeesh Bayry
Journal:  Nat Rev Rheumatol       Date:  2021-10-29       Impact factor: 20.543

8.  Protective Effect of TNFRSF11A rs7239667 G > C Gene Polymorphism on Coronary Outcome of Kawasaki Disease in Southern Chinese Population.

Authors:  Linyuan Zhang; Kun Lin; Yishuai Wang; Hongyan Yu; Jinqing Li; Lanyan Fu; Yufen Xu; Bing Wei; Hanran Mai; Zhiyong Jiang; Di Che; Lei Pi; Xiaoqiong Gu
Journal:  Front Genet       Date:  2021-08-17       Impact factor: 4.599

9.  Anti-inflammatory effects of infliximab in mice are independent of tumour necrosis factor α neutralization.

Authors:  M B Assas; S E Levison; M Little; H England; L Battrick; J Bagnall; J T McLaughlin; P Paszek; K J Else; J L Pennock
Journal:  Clin Exp Immunol       Date:  2016-11-23       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.